Alterations in the Abundance and Co-occurrence of Akkermansia muciniphila and Faecalibacterium prausnitzii in the Colonic Mucosa of Inflammatory Bowel Disease Subjects

Frontiers in Cellular and Infection Microbiology

Volumn 8, Issue SEP, 2018, Pages

  Lopez Siles, Mireia ^a   Enrich Capó, Núria ^a   Aldeguer, Xavier ^b   Sabat Mir, Miriam ^c   Duncan, Sylvia H ^d   Garcia Gil, L Jesús ^a   Martinez Medina, Margarita ^a  

^a UNIVERSITY OF GIRONA   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c HOSPITAL SANTA CATERINA   (Spain)

^d ROWETT RESEARCH INSTITUTE   (United Kingdom)

Author keywords

Akkermansia muciniphila; Crohn's disease; Faecalibacterium prausnitzii; Inflammatory bowel diseases; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AGENTS USED IN INFLAMMATORY BOWEL DISEASE; BACTERIAL RNA; BIOLOGICAL MARKER; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; RNA 16S;

ADULT; AGED; AKKERMANSIA MUCINIPHILA; ARTICLE; BACTERIAL LOAD; COHORT ANALYSIS; COLON BIOPSY; COLON MUCOSA; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; FAECALIBACTERIUM; FAECALIBACTERIUM PRAUSNITZII; FEMALE; GENE DOSAGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; POPULATION ABUNDANCE; QUANTITATIVE ASSAY; ULCERATIVE COLITIS; BIOPSY; COLON; GENETICS; GRAM NEGATIVE INFECTION; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MIXED INFECTION; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; VERRUCOMICROBIA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BACTERIAL LOAD; BIOPSY; COINFECTION; COLON; FAECALIBACTERIUM PRAUSNITZII; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PREVALENCE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, RIBOSOMAL, 16S; VERRUCOMICROBIA; YOUNG ADULT;

EID: 85055200410     PISSN: None     EISSN: 22352988     Source Type: Journal    
DOI: 10.3389/fcimb.2018.00281     Document Type: Article

References (76)

1. Andoh, A., Tsujikawa, T., Sasaki, M., Mitsuyama, K., Suzuki, Y., Matsui, T., et al. (2009). Faecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism analysis. Aliment. Pharmacol. Ther. 29, 75-82. doi:10.1111/j.1365-2036.2008.03860.x.
2. Antoni, L., Nuding, S., Wehkamp, J., and Stange, E. F. (2014). Intestinal barrier in inflammatory bowel disease. World J. Gastroenterol. 20, 1165-1179. doi:10.3748/wjg.v20.i5.1165.
3. Balamurugan, R., Rajendiran, E., George, S., Samuel, G. V., and Ramakrishna, B. S. (2008). Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J. Gastroenterol. Hepatol. 23, 1298-1303. doi:10.1111/j.1440-1746.2008.05490.x.
4. Barkas, F., Liberopoulos, E., Kei, A., and Elisaf, M. (2013). Electrolyte and acid-base disorders in inflammatory bowel disease. Ann. Gastroenterol. 26, 23-28.
5. Baumgart, M., Dogan, B., Rishniw, M., Weitzman, G., Bosworth, B., Yantiss, R., et al. (2007). Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 1, 403-418. doi:10.1038/ismej.2007.52.
6. Belzer, C., Chia, L. W., Aalvink, S., Chamlagain, B., Piironen, V., Knol, J., et al. (2017). Microbial metabolic networks at the mucus layer lead to diet-independent butyrate and vitamin B12 production by intestinal symbionts. MBio 8: 00770-17. doi:10.1128/mBio.00770-17.
7. Belzer, C., and de Vos, W. M. (2012). Microbes inside-from diversity to function: The case of Akkermansia. ISME J. 6:1449. doi:10.1038/ismej.2012.6.
8. Benevides, L., Burman, S., Martin, R., Robert, V., Thomas, M., Miquel, S., et al. (2017). New Insights into the diversity of the genus Faecalibacterium. Front. Microbiol. 8:1790. doi:10.3389/fmicb.2017.01790.
9. Best, W. R., Becktel, J. M., Singleton, J. W., and Kern, F. Jr. (1976). Development of a Crohn's disease activity index. National Cooperative Crohn's disease study. Gastroenterology 70, 439-444. doi:10.1016/S0016-5085(76)80163-1.
10. Candela, M., Rampelli, S., Turroni, S., Severgnini, M., Consolandi, C., De Bellis, G., et al. (2012). Unbalance of intestinal microbiota in atopic children. BMC Microbiol. 12:95. doi:10.1186/1471-2180-12-95.
11. Carlsson, A. H., Yakymenko, O., Olivier, I., Håkansson, F., Postma, E., Keita, A. V., et al. (2013). Faecalibacterium prausnitzii supernatant improves intestinal barrier function in mice DSS colitis. Scand. J. Gastroenterol. 48, 1136-1144. doi:10.3109/00365521.2013.828773.
12. Collado, M. C., Derrien, M., Isolauri, E., de Vos, W. M., and Salminen, S. (2007). Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl. Environ. Microbiol. 73, 7767-7770. doi:10.1128/AEM.01477-07.
13. De Palma, G., Nadal, I., Collado, M. C., and Sanz, Y. (2009). Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects. Br. J. Nutr. 102, 1154-1160. doi:10.1017/S0007114509371767.
14. Derrien, M., Collado, M. C., Ben-Amor, K., Salminen, S., and de Vos, W. M. (2008). The mucin degrader Akkermansia muciniphila is an abundant resident of the human intestinal tract. Appl. Environ. Microbiol. 74, 1646-1648. doi:10.1128/AEM.01226-07.
15. Derrien, M., Van Baarlen, P., Hooiveld, G., Norin, E., Müller, M., and de Vos, W. M. (2011). Modulation of mucosal immune response, tolerance, and proliferation in mice colonized by the mucin-degrader Akkermansia muciniphila. Front. Microbiol. 2:166. doi:10.3389/fmicb.2011.00166.
16. Derrien, M., Vaughan, E. E., Plugge, C. M., and de Vos, W. M. (2004). Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 54, 1469-1476. doi:10.1099/ijs.0.02873-054/5/1469.
17. Dörffel, Y., Swidsinski, A., Loening-Baucke, V., Wiedenmann, B., and Pavel, M. (2012). Common biostructure of the colonic microbiota in neuroendocrine tumors and Crohn's disease and the effect of therapy. Inflamm. Bowel Dis. 18, 1663-1671. doi:10.1002/ibd.21923.
18. Duncan, S. H., Hold, G. L., Harmsen, H. J., Stewart, C. S., and Flint, H. J. (2002). Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. Int. J. Syst. Evol. Microbiol. 52, 2141-2146. doi:10.1099/00207713-52-6-2141.
19. Everard, A., Belzer, C., Geurts, L., Ouwerkerk, J. P., Druart, C., Bindels, L. B., et al. (2013). Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. U.S.A. 110, 9066-9071. doi:10.1073/pnas.1219451110.
20. Flint, H. J., Scott, K. P., Louis, P., and Duncan, S. H. (2012). The role of the gut microbiota in nutrition and health. Nat. Rev. Gastroenterol. Hepatol. 9, 577-589. doi:10.1038/nrgastro.2012.156.
21. Foditsch, C., Santos, T. M., Teixeira, A. G., Pereira, R. V., Dias, J. M., Gaeta, N., et al. (2014). Isolation and characterization of Faecalibacterium prausnitzii from calves and piglets. PLoS ONE 9: 116465. doi:10.1371/journal.pone.0116465.
22. Frank, D. N., St Amand, A. L., Feldman, R. A., Boedeker, E. C., Harpaz, N., and Pace, N. R. (2007). Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U.S.A. 104, 13780-13785. doi:10.1073/pnas.0706625104.
23. Furet, J.-P., Firmesse, O., Gourmelon, M., Bridonneau, C., Tap, J., Mondot, S., et al. (2009). Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR. FEMS Microbiol. Ecol. 68, 351-362. doi:10.1111/j.1574-6941.2009.00671.x.
24. Furet, J. P., Kong, L. C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J. L., et al. (2010). Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: Links with metabolic and low-grade inflammation markers. Diabetes 59, 3049-3057. doi:10.2337/db10-0253.
25. Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., et al. (2017). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97-103. doi:10.1126/science.aan4236.
26. Gophna, U., Sommerfeld, K., Gophna, S., Doolittle, W. F., and Veldhuyzen van Zanten, S. J. (2006). Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 44, 4136-4141. doi:10.1128/JCM.01004-06.
27. Graessler, J., Qin, Y., Zhong, H., Zhang, J., Licinio, J., Wong, M. L., et al. (2012). Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: Correlation with inflammatory and metabolic parameters. Pharmacogenomics J. 13, 514-522. doi:10.1038/tpj.2012.43.
28. Hansen, R., Russell, R. K., Reiff, C., Louis, P., McIntosh, F., Berry, S. H., et al. (2012). Microbiota of de-novo pediatric IBD: Increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am. J. Gastroenterol. 107, 1913-1922. doi:10.1038/ajg.2012.335.
29. Jia, W., Whitehead, R. N., Griffiths, L., Dawson, C., Waring, R. H., Ramsden, D. B., et al. (2010). Is the abundance of Faecalibacterium prausnitzii relevant to Crohn's disease? FEMS Microbiol. Lett. 310, 138-144. doi:10.1111/j.1574-6968.2010.02057.x.
30. Joossens, M., Huys, G., Cnockaert, M., De Preter, V., Verbeke, K., Rutgeerts, P., et al. (2011). Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut 60, 631-637. doi:10.1136/gut.2010.223263.
31. Kabeerdoss, J., Sankaran, V., Pugazhendhi, S., and Ramakrishna, B. S. (2013). Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: A case-control study in India. BMC Gastroenterol. 13:20. doi:10.1186/1471-230X-13-20.
32. Kang, C.-S., Ban, M., Choi, E.-J., Moon, H.-G., Jeon, J.-S., Kim, D.-K., et al. (2013). Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS ONE 8: 76520. doi:10.1371/journal.pone.0076520.
33. Lane, D. J. (1991). "16S/23S rRNA sequencing, " in Nucleic Acid Techniques in Bacterial Systematics. eds E. Stackebrandt and M. Goodfellow (New York, NY: John Wiley and Sons), 115-175.
34. Lopez-Siles, M., Khan, T. M., Duncan, S. H., Harmsen, H. J., Garcia-Gil, L. J., and Flint, H. J. (2012). Cultured representatives of two major phylogroups of human colonic Faecalibacterium prausnitzii can utilize pectin, uronic acids, and host-derived substrates for growth. Appl. Environ. Microbiol. 78, 420-428. doi:10.1128/AEM.06858-11.
35. Lopez-Siles, M., Martinez-Medina, M., Abellà, C., Busquets, D., Sabat-Mir, M., Duncan, S. H., et al. (2015). Mucosa-associated Faecalibacterium prausnitzii phylotype richness is reduced in patients with inflammatory bowel disease. Appl. Environ. Microbiol. 81, 7582-7592. doi:10.1128/AEM.02006-15.
36. Lopez-Siles, M., Martinez-Medina, M., Busquets, D., Sabat-Mir, M., Duncan, S. H., Flint, H. J., et al. (2014). Mucosa-associated Faecalibacterium prausnitzii and Escherichia coli co-abundance can distinguish irritable bowel syndrome and inflammatory bowel disease phenotypes. Int. J. Med. Microbiol. 304, 464-475. doi:10.1016/j.ijmm.2014.02.009.
37. Lopez-Siles, M., Martinez-Medina, M., Surís-Valls, R., Aldeguer, X., Sabat-Mir, M., Duncan, S. H., et al. (2016). Changes in the abundance of Faecalibacterium prausnitzii phylogroups I and II in the intestinal mucosa of inflammatory bowel disease and patients with colorectal cancer. Inflamm. Bowel Dis. 22, 28-41. doi:10.1097/MIB.0000000000000590.
38. Lozupone, C., Faust, K., Raes, J., Faith, J. J., Frank, D. N., Zaneveld, J., et al. (2012). Identifying genomic and metabolic features that can underlie early successional and opportunistic lifestyles of human gut symbionts. Genome Res. 22, 1974-1984. doi:10.1101/gr.138198.112.
39. Lukovac, S., Belzer, C., Pellis, L., Keijser, B. J., de Vos, W. M., Montijn, R. C., et al. (2014). Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids. MBio 5, e01438-e01414. doi:10.1128/mBio.01438-14.
40. Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., et al. (2013). A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275-1283. doi:10.1136/gutjnl-2013-304833.
41. Manichanh, C., Borruel, N., Casellas, F., and Guarner, F. (2012). The gut microbiota in IBD. Nat. Rev. Gastroenterol. Hepatol. 9, 599-608. doi:10.1038/nrgastro.2012.152.
42. Manichanh, C., Rigottier-Gois, L., Bonnaud, E., Gloux, K., Pelletier, E., Frangeul, L. et al. (2006). Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut 55, 205-211. doi:10.1136/gut.2005.073817.
43. Martín, R., Chain, F., Miquel, S., Lu, J., Gratadoux, J. J., Sokol, H., et al. (2014). The commensal bacterium Faecalibacterium prausnitzii is protective in DNBS-induced chronic moderate and severe colitis models. Inflamm. Bowel Dis. 20, 417-430. doi:10.1097/01.MIB.0000440815.76627.64.
44. Martín, R., Miquel, S., Benevides, L., Bridonneau, C., Robert, V., Hudault, S., et al. (2017). Functional characterization of novel Faecalibacterium prausnitzii strains isolated from healthy volunteers: A step forward in the use of F. prausnitzii as a Next-Generation Probiotic. Front. Microbiol. 8:1226. doi:10.3389/fmicb.2017.01226.
45. Martín, R., Miquel, S., Chain, F., Natividad, J. M., Jury, J., Lu, J., et al. (2015). Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model. BMC Microbiol. 15:67. doi:10.1186/s12866-015-0400-1.
46. Martinez-Medina, M., Aldeguer, X., Gonzalez-Huix, F., Acero, D., and Garcia-Gil, L. J. (2006). Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm. Bowel Dis. 12, 1136-1145. doi:10.1097/01.mib.0000235828.09305.0c.
47. McLaughlin, S. D., Clark, S. K., Tekkis, P. P., Nicholls, R. J., and Ciclitira, P. J. (2010). The bacterial pathogenesis and treatment of pouchitis. Therap. Adv. Gastroenterol. 3, 335-348. doi:10.1177/1756283X10370611.
48. Mendoza Hernández, J. L., Lana Soto, R., and Díaz-Rubio, M. (2007). Definiciones y Manifestaciones Clínicas Generales. Madrid: Arán Ediciones S.L.
49. Miquel, S., Martín, R., Rossi, O., Bermúdez-Humarán, L., Chatel, J., Sokol, H., et al. (2013). Faecalibacterium prausnitzii and human intestinal health. Curr. Opin. Microbiol. 16, 255-261. doi:10.1016/j.mib.2013.06.003.
50. Mira-Pascual, L., Cabrera-Rubio, R., Ocon, S., Costales, P., Parra, A., Suarez, A., et al. (2015). Microbial mucosal colonic shifts associated with the development of colorectal cancer reveal the presence of different bacterial and archaeal biomarkers. J. Gastroenterol. 50, 167-179. doi:10.1007/s00535-014-0963-x.
51. Mondot, S., Kang, S., Furet, J. P., Aguirre de Carcer, D., McSweeney, C., Morrison, M., et al. (2011). Highlighting new phylogenetic specificities of Crohn's disease microbiota. Inflamm. Bowel Dis. 17, 185-192. doi:10.1002/ibd.21436.
52. Neef, A., and Sanz, Y. (2013). Future for probiotic science in functional food and dietary supplement development. Curr. Opin. Clin. Nutr. Metab. Care 16, 679-687. doi:10.1097/MCO.0b013e328365c258.
53. Nugent, S. G., Kumar, D., Rampton, D. S., and Evans, D. F. (2001). Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut 48, 571-577. doi:10.1136/gut.48.4.571.
54. Pineton de Chambrun, G., Peyrin-Biroulet, L., Lémann, M., and Colombel, J. F. (2010). Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 7, 15-29. doi:10.1038/nrgastro.2009.203.
55. Png, C. W., Lindén, S. K., Gilshenan, K. S., Zoetendal, E. G., McSweeney, C. S., Sly, L. I., et al. (2010). Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am. J. Gastroenterol. 105, 2420-2428. doi:10.1038/ajg.2010.281.
56. Rajilić-Stojanović, M., Biagi, E., Heilig, H. G., Kajander, K., Kekkonen, R. A., Tims, S., et al. (2011). Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792-1801. doi:10.1053/j.gastro.2011.07.043.
57. Rios-Covian, D., Gueimonde, M., Duncan, S. H., Flint, H. J., and de los Reyes-Gavilan, C. G. (2015). Enhanced butyrate formation by cross-feeding between Faecalibacterium prausnitzii and Bifidobacterium adolescentis. FEMS Microbiol. Lett. 362:fnv176. doi:10.1093/femsle/fnv176.
58. Rossi, O., Khan, M. T., Schwarzer, M., Hudcovic, T., Srutkova, D., Duncan, S. H., et al. (2015). Faecalibacterium prausnitzii strain HTF-F and its extracellular polymeric matrix attenuate clinical parameters in DSS-induced colitis. PLoS ONE 10: 0123013. doi:10.1371/journal.pone.0123013.
59. Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., et al. (2017). Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91-97. doi:10.1126/science.aan3706.
60. Sartor, R. B. (2006). Mechanisms of disease: Pathogenesis of Crohn's disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3, 390-407. doi:10.1038/ncpgasthep0528.
61. Sartor, R. B. (2008). Microbial influences in inflammatory bowel diseases. Gastroenterology 134, 577-594. doi:10.1053/j.gastro.2007.11.059.
62. Seksik, P., Sokol, H., Lepage, P., Vasquez, N., Manichanh, C., Mangin, I., et al. (2006). Review article: The role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment. Pharmacol. Ther. 24, 11-18. doi:10.1111/j.1365-2036.2006.03053.x.
63. Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., et al. (2005). Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. 19, 5A-36A. doi:10.1155/2005/269076.
64. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J. J., et al. (2008). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U.S.A. 105, 16731-16736. doi:10.1073/pnas.0804812105.
65. Sokol, H., and Seksik, P. (2010). The intestinal microbiota in inflammatory bowel diseases: Time to connect with the host. Curr. Opin. Gastroenterol. 26, 327-331. doi:10.1097/MOG.0b013e328339536.
66. Sokol, H., Seksik, P., Furet, J. P., Firmesse, O., Nion-Larmurier, I., Beaugerie, L., et al. (2009). Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15, 1183-1189. doi:10.1002/ibd.20903.
67. Stoddard, S. F., Smith, B. J., Hein, R., Roller, B. R., and Schmidt, T. M. (2015). rrnDB: Improved tools for interpreting rRNA gene abundance in bacteria and archaea and a new foundation for future development. Nucleic Acids Res. 43, D593-D598. doi:10.1093/nar/gku1201.
68. Swidsinski, A., Dörffel, Y., Loening-Baucke, V., Theissig, F., Rückert, J. C., Ismail, M., et al. (2011). Acute appendicitis is characterised by local invasion with Fusobacterium nucleatum/necrophorum. Gut 60, 34-40. doi:10.1136/gut.2009.191320.
69. Swidsinski, A., Loening-Baucke, V., Lochs, H., and Hale, L. P. (2005). Spatial organization of bacterial flora in normal and inflamed intestine: A fluorescence in situ hybridization study in mice. World. J. Gastroenterol. 11, 1131-1140. doi:10.3748/wjg.v11.i8.1131.
70. Swidsinski, A., Loening-Baucke, V., Vaneechoutte, M., and Doerffel, Y. (2008). Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm. Bowel Dis. 14, 147-161. doi:10.1002/ibd.20330.
71. van Passel, M. W., Kant, R., Zoetendal, E. G., Plugge, C. M., Derrien, M., Malfatti, S. A., et al. (2011). The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. PLoS ONE 6: 16876. doi:10.1371/journal.pone.0016876.
72. Vermeiren, J., Van den Abbeele, P., Laukens, D., Vigsnaes, L. K., De Vos, M., Boon, N., et al. (2012). Decreased colonization of fecal Clostridium coccoides/Eubacterium rectale species from ulcerative colitis patients in an in vitro dynamic gut model with mucin environment. FEMS Microbiol. Ecol. 79, 685-696. doi:10.1111/j.1574-6941.2011.01252.x.
73. Weir, T. L., Manter, D. K., Sheflin, A. M., Barnett, B. A., Heuberger, A. L., and Ryan, E. P. (2013). Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS ONE 8: 70803. doi:10.1371/journal.pone.0070803.
74. Weisburg, W. G., Barns, S. M., Pelletier, D. A., and Lane, D. J. (1991). 16S ribosomal DNA amplification for phylogenetic study. J. Bacteriol. 173, 697-703.
75. Willing, B., Halfvarson, J., Dicksved, J., Rosenquist, M., Järnerot, G., Engstrand, L., et al. (2009). Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm. Bowel Dis. 15, 653-660. doi:10.1002/ibd.20783.
76. Wrzosek, L., Miquel, S., Noordine, M. L., Bouet, S., Joncquel Chevalier-Curt, M., Robert, V., et al. (2013). Bacteroides thetaiotaomicron and Faecalibacterium prausnitzii influence the production of mucus glycans and the development of goblet cells in the colonic epithelium of a gnotobiotic model rodent. BMC Biol. 11:61. doi:10.1186/1741-7007-11-61.